Clinical Trials Logo

Advanced Biliary Tract Cancer clinical trials

View clinical trials related to Advanced Biliary Tract Cancer.

Filter by:

NCT ID: NCT04733521 Not yet recruiting - Clinical trials for Advanced Biliary Tract Cancer

A Phase 1/2 Study of SC-43 in Combination With Cisplatin

Start date: May 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma

NCT ID: NCT04727996 Active, not recruiting - Clinical trials for Advanced Biliary Tract Cancer

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

BTC-BGB
Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.

NCT ID: NCT04217954 Completed - Clinical trials for Advanced Biliary Tract Cancer

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary malignant tumors.

NCT ID: NCT04211168 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Start date: August 11, 2020
Phase: Phase 2
Study type: Interventional

The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers and to analyze potential biomarkers of therapeutic response.

NCT ID: NCT04172402 Active, not recruiting - Clinical trials for Advanced Biliary Tract Cancer

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

Start date: December 27, 2019
Phase: Phase 2
Study type: Interventional

To evaluate disease objective response rate (ORR) of nivolumab in combination with gemcitabine and TS1 in patients with advanced biliary tract cancer

NCT ID: NCT04027764 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer. treatment continually until disease progression or intolerable toxicity or Patients withdrawal of consent.and target sample is 30+ patients.

NCT ID: NCT04005339 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Start date: July 29, 2019
Phase: Phase 2
Study type: Interventional

This is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy.

NCT ID: NCT03358849 Completed - Clinical trials for Advanced Biliary Tract Cancer

Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer

Start date: October 17, 2017
Phase: Phase 1
Study type: Interventional

Cholangiocarcinoma refers to bile duct cancer (bile duct cancer) and gallbladder cancer that develop in the gallbladder. According to the data from National Cancer Information Center in 2013, the incidence of cancer in Korea is 5,283, which corresponds to about 2.3% of all cancers and the 5-year survival rate is 30% And most of the long-term survival is due to early detection by screening, and advanced carcinoma is a refractory carcinoma with a 5-year survival rate of less than 5%. In addition to the standard anticancer drugs, alternative anticancer drugs and targeted therapies have been developed to provide a variety of treatment modalities. However, the development of cell therapy drugs for cancer, such as cancers, has not been developed in Korea. . Natural killer cells (NK cells) are innate lymphocyte cells with cytotoxic activity. Unlike T cells and B cells, which have antigen-specific receptors, NK cells express various innate immunoreceptors on the cell surface, thereby enabling selective recognition of cancer cells And recognizes cancer cells, it is a cytotoxic cell that can immediately remove cancer cells without any other activation process. In addition, natural killer cells also interact with dendritic cells or T cells directly or indirectly to regulate the immune response, thereby inhibiting the development and metastasis of cancer cells and effectively removing cancer stem cells important for cancer recurrence It has many advantages in the development of anti-cancer immunotherapy.

NCT ID: NCT02597465 Withdrawn - Clinical trials for Advanced Biliary Tract Cancer

A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507

Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

An open label study to determine the efficacy and safety of SPARC1507